Donepezil for Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 7, Issue 10, 2007, Pages 1243-1249

  Benjamin, Boben ^a   Burns, Alistair ^a  

^a Wythenshawe Hopsital   (United Kingdom)

Author keywords

Alzheimer's dementia; Cholinesterase inhibitor; Donepezil

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ANOREXIA; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ECCHYMOSIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; MUSCLE CRAMP; NAUSEA; NEUROTRANSMISSION; REVIEW; RISK FACTOR; SIDE EFFECT; STOMACH ACID SECRETION; VOMITING;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES;

EID: 35548935721     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.10.1243     Document Type: Review

References (73)

1. American Psychiatric Association (APA). In: Diagnostic and Statistical Manual (3rd Edition). American Psychiatric Association, WA, USA (1993).
2. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA workgroup under the auspices of the Department of Health and Human Services taskforce on Alzheimer's disease. Neurology 34, 939-944 (1984).
3. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 22(8), 806-812 (2007). • Study demonstrating the efficacy and safety of donepezil in the long term.
4. Burns A, O'Brien J. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. 20(6), 732-755 (2006).
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 25(1), CD005593 (2006).
6. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 1, 859-866 (2002).
7. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2, 539-547 (2003).
8. Chalifour RJ, McLaughlin RW, Lavoie L et al. Stereoselective interactions of peptide inhibitors with the β-amyloid peptide. J. Biol. Chem. 278, 34874-34881(2003).
9. Huang TH, Yang DS, Plaskos NP et al. Structural studies of soluble oligomers of the Alzheimer amyloid peptide. J. Mol. Biol. 297, 73-87 (2000).
10. Rueter LE, Anderson DJ, Briggs CA et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 10, 167-182 (2004).
11. Guo T, Hobbs DW. Development of BACE1 inhibitors in Alzheimer's disease. Curr. Med. Chem. 13(15), 1811-1129 (2006).
12. Lynch G. Glutamate-based therapeutic approach: ampakine. Curr. Opin. Pharmacol. 6, 82-88 (2006).
13. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63(2), 214-219 (2004).
14. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am. J. Health Syst. Pharm. 54(24), 2805-2810 (1997).
15. Ibach B, Haen F. Acetylcholinesterase inhibition in Alzheimer's disease. Curr. Pharm. Des. 10(3), 231-251 (2004).
16. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch. Neurol. 30, 113-121 (1974).
17. Bowen DM, Smith CB, White P et al. Chemical pathology of the organic dementias. II. Quantitative estimation of cellular changes in post-mortem brains Brain 100, 427-453 (1977).
18. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237-1239 (1982).
19. Narahashi T, Moriguchi S, Zhao X et al. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol. Pharm. Bull. 27(11), 1701-1706 (2004).
20. Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in AD and related cognitive disorders: the cholinergic-vascular hypothesis. J. Gerontol. A Biol. Sci. Med. Sci. 61(3), 267-271 (2006).
21. Takatori Y. Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease. Yakugaku Zasshi 126(8) 607-616 (2006).
22. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis. Assoc. Disord. 20(2 Suppl. 1), S8-S11 (2006).
23. Takoda-Takatori Y, Kume T, Sugunoto M et al. Acetylcholinesterase inhibitors used in the treatment of AD prevent glutamate neurotoxicity via nicotine acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharamacology 51(3), 474-486 (2006).
24. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in AD. Alzheimer Dis. Assoc. Disord. 20(2 Suppl. 1), S8-S12 (2006).
25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 4, 1356-1364 (1984).
26. Sramek JJ, Cutler NR. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer Dis. Assoc. Disord. 4, 216-227 (2000).
27. Hashimoto M, Kazui H, Matsumoto K et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am. J. Psychiatry 162(4), 676-682 (2005).
28. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159(5), 738-745 (2002).
29. Krishnan KR, Charles HC, Doraiswamy PM et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. J. Psychiatry 160(11), 2003-2011 (2003).
30. 11CCP-126,998, a brain selective enzyme inhibitor. Synapse 45(1), 1-9 (2002).
31. Seltzer B. Donepezil: a review. Expert Opin. Drug Metab. Toxicol. 1(3), 527-536 (2005).
32. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br. J. Clin. Pharmacol. 46(Suppl. 1), 1-6 (1998).
33. Tiseo PJ, Rogers SL, Friedoff LT. Pharmacokinetic and Pharmacodynamic profile of donepezil HCL following evening administration. Br. J. Clin. Pharmacol. 46(Suppl. 1), 19-24 (1998).
34. Tiseo PJ, Perdomo CA, Friedoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study Br. J. Clin. Pharmacol. 46(Suppl. 1), 19-24 (1998).
35. Ravic M, Warrington S, Boyce M, Dunn K, Johnston A. Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers. Br. J. Clin. Pharmacol. 58(Suppl. 1), 34-40 (2004).
36. Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br. J. Clin. Pharmacol. 58(Suppl. 1), 25-33 (2004).
37. Nagy CF, Kumar D, Cullen EI et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br. J. Clin. Pharmacol. 58(Suppl. 1), 18-24 (2004).
38. Reyes JF, Vargas R, Kumar D, Cullen EI, Perdomo CA, Pratt RD. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br. J. Clin. Pharmacol. 58(Suppl. 1), 9-17 (2004).
39. Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J. Safety and efficacy of donepezil in African-Americans with mild-to-moderate Alzheimer's disease. J. Natl Med. Assoc. 98(10), 1590-1597 (2006).
40. Alagiakrishnan K, Wong W, Blanchette PL. Use of donepezil in elderly patients with Alzheimer's disease - a Hawaii based study. Hawaii Med. J. 59(2), 57-59 (2000).
41. Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 31(5) 223-229 (1993).
42. Heywood WM, Mukaetova-Ladinska EB. Sex influence on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. Am. J. Geriatr. Pharmacother. 4(3), 273-286 (2006).
43. Rogers SL, Friedoff LT. Donepezil study group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The donepezil study group. Dementia 7(6), 293-303 (1996). • Pivotal clinical trial.
44. Rogers SL, Doody RS, Mohs RC et al. Donepezil improves cognitive and global functioning: a 15 week, double-blind placebo controlled trial. Arch. Int. Med. 158(9) 1021-1031 (1998). • Pivotal clinical trial.
45. Rogers SL, Farlow MR, Doody RS et al. A 24 week double-blind, placebo controlled trial in patients with Alzheimer's disease. Neurology 50(1), 136-145 (1998). • Pivotal clinical trial.
46. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease- results from a multi-national trial. Dement. Geriatr. Cogn. Disord. 10(3), 237-244 (1999). • Pivotal clinical trial.
47. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo controlled preservation of function survival study of donepezil in AD patients. Neurology 57, 481-488 (2001).
48. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med. 158, 1021-1031 (1998).
49. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50, 136-145 (1998).
50. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57, 489-495 (2001).
51. Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, Phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol. 58, 427-433 (2001).
52. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol. 10, 195-203 (2000).
53. Winblad B, Wimo A, Engedal K et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement. Geriatr. Cogn. Disord. 21(5-6), 353-363 (2006).
54. Feldman H, Gauthier S, Hecker J et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on carer burden. J. Am. Geriatr. Soc. 51(6), 734-744 (2003).
55. Seltzer B, Zolnouni P, Nunez M et al. Efficacy of donepezil in early-stage Alzheimer's disease: a randomized placebo controlled trial. Arch. Neurol. 61(12), 1852-1856 (2004).
56. Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzhiemer's disease. Int. Psychogeriatr. 12(3) 389-401 (2000).
57. Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63(4), 651-657 (2004).
58. Peterson RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352(23), 2379-2388 (2005).
59. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3), 317-324 (2004).
60. Bordier P, Garrique S, Barold SS, Bressolles N, Lanusse S, Clementy J. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 5(4), 429-431 (2003).
61. Newby JV, Kenny AR, McKeith IG. Case report of donepezil associated cardiac syncope. Int. J. Geriatr. Psychiatry 19(11), 1110-1112 (2004).
62. Babic T, Zurak N. Convulsions induced by donepezil. J. Neurol. Neurosurg. Psychiatr. 66(3), 410 (1999).
63. Thacker EL, Schneeweiss S. Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients. Drug Saf. 29(11), 1077-1085 (2006).
64. Lopez-Paisa S, Olmo JP, French JV et al. Comparative analysis of mortality in patients with AD treated with donepezil or galantamine. Age Ageing 35(4), 365-371 (2006).
65. Scatena R, Martorana GE, Bottoni P et al. An update on pharmacological approaches to neurodegenerative diseases. Expert Opin. Investig. Drugs 16(1), 59-72 (2007). • Review of new drugs for Alzheimer's disease currently in clinical trials.
66. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety and confirmation of a pathogenic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7(1), 10-28 (2007).
67. Alzheimer's Association. Alzheimer's disease facts and figures 2007 www.alz.org/national/documents/Report_2007FactsAndFigures.pdf
68. Dementia UK. A report into the prevalence and cost of dementia prepared by the Personal Social Services Research Unit (PSSRU) at the London School of Economics and the Institute of Psychiatry at King's College London for the Alzheimer's Society www.alzheimers.org.uk/News_and_Campaigns/Campaigning/PDF/ Dementia_UK
69. National Institute for Health and Clinical Excellence www.NICE.org.uk
70. The treatment of AD, Study IX Market Measure/Cozint, NOP World, May 2003 www.nopworld.com
71. Prescribing information, Ortho-McNeil Neurologics www.fda.gov/medWatch/ SAFETY/2005/reminylDDLmarch.pdf
72. EISAI Co., Ltd www.eisai.co.jp/enews/enews200609.html
73. US FDA www.fda.gov/bbs/topics/NEWS/2006/NEW01491.html